Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

 Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Shots:

  • The P-I/II dose expansion studies evaluate the safety & preliminary anti-tumor efficacy of VT1021 as monothx. in patients with dose-escalation & expansion cohorts with rGBM & PC. The results of both studies are expected in Q4’21
  • In the rGBM expansion cohort, the therapy showed a complete tumor regression & PR, patients remain on trial for ~9mos. & continue to receive therapy in an open-label extension study. In PC expansion cohort, reduction in tumor with measurable disease & able to reprogram tumor immune microenvironment from immune-suppressive to immune-responsive
  • The company plans to initiate a P-II/III study of VT1021 for newly diagnosed & recurrent GBM patients at the end of 2021

Click here to­ read full press release/ article | Ref: Vigeo | Image: Reuter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post